GlassScriptPhysician profile
Dawn M Turner
NPI 1669889317
$1,008.35
in general payments reported to CMS, 2019-2025
19 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $247 · 2024: $380 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Education: $56.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.95 |
| Education | $56.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $257.19 | 2024-2025 | Calquence, Datroway |
| Novartis Pharmaceuticals Corporation | $134.95 | 2023-2025 | |
| Janssen Biotech, INC. | $93.72 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $79.01 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $73.10 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $67.60 | 2023-2024 | Keytruda |
| Pfizer INC. | $44.36 | 2024-2025 | |
| Pharmaessentia USA Corporation | $32.42 | 2023 | Besremi |
| Astellas Pharma US INC | $32.11 | 2025 | Vyloy |
| Genzyme Corporation | $29.39 | 2023 | |
| Daiichi Sankyo INC. | $29.04 | 2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $23.63 | 2025 | Opdivo |
| Glaxosmithkline, LLC. | $18.55 | 2023 | Ojjaara |
| Sobi, INC | $18.54 | 2024 | |
| Beigene USA, INC. | $15.79 | 2023 | Brukinsa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $15.75 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.62 | 2023 | Somatuline Depot, Onivyde |
| Blueprint Medicines Corporation | $15.40 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.